REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme

Trial Profile

REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Basiliximab (Primary) ; Cancer vaccine-pp65 (Primary) ; Autolymphocyte therapy; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms REGULATe
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results (n=28) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 21 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top